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ABSTRACT
Cystic fibrosis (CF) is the most common genetic
disease affecting the Caucasian population.
Chronic Pseudomonas aeruginosa pulmonary
infection is the major cause of morbidity and
mortality in CF patients. Human beta-defensin-
2 (hBD-2) is an inducible pulmonary
antimicrobial peptide that exerts bacteriostatic
activity in a concentration-dependent manner.
The decreased expression and compromised
function of hBD-2 contributes to the
pathogenesis of P. aeruginosa infection in the
CF lung. The purpose of this review is to outline
the significance of hBD-2 in P. aeruginosa
chronic pulmonary infection in CF patients.
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INTRODUCTION
The average human inhales *10,000 L of air
every day. Respiration is a portal of entry for not
only atmospheric gases, but also for harmful
particulate pervasive in the environment. The
pulmonary epithelium is therefore continually
exposed to microorganisms, but remains sterile
under normal physiologic conditions. This
remarkable phenomenon is a testament to the
innate immune defenses that provide a silent
mode of broad immune protection. The
importance of the innate immune system in
protecting the lungs from infection is clearly
illustrated in the pathologic condition that
arises in cystic fibrosis (CF) (mucoviscidosis),
which severely damages the pulmonary innate
immune defenses [1].
Cystic fibrosis is the most common lethal
genetic disorder affecting the Caucasian
population, with an incidence of 1 in 2,500
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births [2]. CF is caused by an autosomal
recessive mutation in the cystic fibrosis
transmembrane conductance regulator (CFTR)
gene within chromosome seven [3]. This
mutation results in the functional defect in
the cyclic adenosine monophosphate
stimulated pulmonary chloride pump causing
abnormal ion transport in epithelial cells [4, 5].
CF is therefore a disease of ion transport across
the epithelium, affecting fluid secretion in
exocrine glands and the epithelium of the
respiratory, reproductive, and gastrointestinal
tracts [6]. Although CF causes a multitude of
pathophysiologic effects, the most significant
effect is the impaired ciliary clearance that
results in the accumulation of mucus in the
lung, creating a haven for bacteria. Moreover,
the dehydrating conditions in the lung caused
by the elevated levels of sodium chloride in the
airway secretions severely weaken the host
pulmonary innate defenses. The initial acute
pulmonary infection of the CF lung is typically
a result of colonization by Haemophilus
influenzae and Staphylococcus aureus, while the
ensuing chronic infection is caused by
Pseudomonas aeruginosa [7, 8]. The chronic
infection in the lungs of CF patients caused by
P. aeruginosa is responsible for the high rate of
morbidity and mortality associated with this
genetic disease [9].
Pseudomonas aeruginosa is a ubiquitous,
antibiotic resistant, Gram-negative
opportunistic bacterium [10]. At 6.3 million
base pairs, the PAO1 strain of P. aeruginosa has
the largest genome sequenced [11]. This large
genome provides the genetic machinery that
enables P. aeruginosa to readily undergo
significant genetic and phenotypic
transformations in response to environmental
changes, contributing to its versatility and
antibiotic resistance potential. Although P.
aeruginosa is pervasive in the environment, it
only causes infection in immunodeficient hosts,
e.g., CF patients, patients with acquired
immunodeficiency syndrome, burn victims,
etc. Among the many clinical manifestations
of P. aeruginosa infection, P. aeruginosa’s
opportunistic mode of infection is most
known in the chronic pulmonary infection
that is the hallmark of CF [12]. Once acquired,
P. aeruginosa almost always colonizes the lungs
of CF patients for life [13].
Human beta-defensin-2 (hBD-2) is a Major
Effector of Innate Immunity
The innate immune system provides the first
line of defense against microorganisms
pervasive in the environment. Unlike the
adaptive immune system, innate immunity is
non-specific, lacks memory, and is not
influenced by previous exposure.
Antimicrobial peptides (AMPs) are cationic
endogenous antibiotic proteins expressed
throughout the epithelium that are effectors of
the innate immune system. AMPs exert
antimicrobial activity in a concentration-
dependent manner, making their expression a
critical factor in host defense [14]. The
amphiphathic nature of AMPs contributes to
their effectiveness at interacting with
hydrophobic and anionic components of the
bacterial membrane [15]. Cathelicidins,
a-defensins, b-defensins, and h-defensins are
among the major classes of human AMPs [16].
Beta-defensins are at the interface between
the adaptive and innate immune systems;
beta-defensins exhibit chemotactic function
towards immature dendritic cells, memory T
cells expressing the chemokine receptor CCR6,
neutrophils primed with tumor necrosis factor
(TNF)-a, and mast cells [17, 18]. Individual
beta-defensins have specific antimicrobial
activity. Among the various types of defensin
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AMPs, only the expression of human beta-
defensin-2 (hBD-2) and human beta-defensin-3
(hBD-3) is increased following stimulation by
pro-inflammatory cytokines; all other defensin
AMPs are continuously expressed [19].
However, although the expression of hBD-2
and hBD-3 can be stimulated by
pro-inflammatory cytokines, e.g., TNF-a,
interleukin (IL)-1b, IL-17, and IL-22, these
antimicrobial peptides are still expressed in
unstimulated cells in basal amounts [20, 21].
An additional difference between these two
AMPs that are induced by humoral stimulation
is that hBD-2 primarily targets Gram-negative
bacteria, such as P. aeruginosa, while hBD-3
exerts broad bacteriostatic activity against both
Gram-positive and Gram-negative bacteria [22].
hBD-2, like all defensins, is found throughout
the epithelium of mammals. However, hBD-2 is
most concentrated in the epithelia of the lung,
tonsils, and trachea, and therefore plays a
critical role in the prevention of pulmonary
infection [23, 24]. The inducible properties of
hBD-2 suggest it plays a significant role in
innate immune defense.
Human beta-defensin-2 is a cationic, 41
amino acid, 4 kDa, AMP intricately involved in
the innate immune response of vertebrates that
works synergistically with other antimicrobial
molecules, such as lactoferrin and lysozyme [24,
25]. Like other beta-defensins, hBD-2 is a
monomeric protein containing six conserved
cysteine residues forming three core disulfide
bonds [26]. The initial contact between hBD-2
and invading microorganisms is an electrostatic
amphipathic attraction between the cationic
AMP and the negatively charged phospholipid
groups of the bacterium’s phospholipid bilayer
[27, 28]. Following initial electrostatic
attraction, hBD-2 exerts its antimicrobial
effects through insertion within the
phospholipid bilayer disrupting the membrane
integrity of the invading bacteria resulting in
the collapse of membrane potential and death
of the invading pathogen [29]. Nuclear
magnetic resonance (NMR) analysis of the
crystal structures of hBD-2 suggests that the
formation of a hBD-2 octamer is a prerequisite
to the binding of the bacteria cell surface and
subsequent increases in membrane permeability
[30].
Decreased hBD-2 Expression Occurs
in Chronic P. aeruginosa Infection
A common theme in pathogen—host
interactions is the selection against virulence
factors required for the establishment of
infection, as the stage the infection shifts from
acute to chronic. Genetic variants are selected
that promote long-term survivability and clonal
expansion, while variants that no longer
provide a survival advantage are selected
against. In the CF lung, P. aeruginosa
undergoes significant genetic and phenotypic
transformations in response to changes in the
pulmonary milieu. P. aeruginosa mutates to a
mucoid, flagella-deficient phenotype over the
course of chronic pulmonary infection [31, 32].
The changes in the expression of P. aeruginosa
virulence factors affect the expression of hBD-2
in the pulmonary epithelium that weakens the
innate immune defense of the lung [33].
Flagellum is a structure common to most
Gram-negative bacteria derived from flagellin
monomers that confers motility, promotes
adhesion, and consequently is a significant
bacterial virulence factor [34]. Flagellum is a
bacterial ligand that is detected by toll-like
receptor (TLR) 5 [35]. The activation of TLR5
by flagellum initiates an inflammatory response
that includes the up-regulation of hBD-2 via a
nuclear factor (NF)-jB dependent pathway in
airway epithelial cells [21]. The loss of flagella
Infect Dis Ther (2013) 2:159–166 161
123
expression during the transition to the mucoid
phenotype allows P. aeruginosa to evade the
antimicrobial activity of hBD-2 through
decreased TLR5 stimulation, contributing to
P. aeruginosa’s pathogenesis in the CF lung
[21, 35].
Some bacterial virulence factors remain
expressed throughout different stages of
infection. Although P. aeruginosa isolates from
the chronic stage of pulmonary infection are
flagella-deficient, other virulence factors, which
are TLR agonists and stimulate hBD-2
expression, remain expressed. For example,
lipopolysaccharide (LPS) is an endotoxin
attached to the outer membrane of Gram-
negative bacteria that is an agonist of TLR 4
[36]. Although LPS expression does not decrease
as pulmonary infection shifts from the acute to
chronic stage, the cellular responsiveness to LPS
decreases.
A study involving the exposure of airway
epithelial cells to a regime of two discrete
bacterial infections demonstrated reduced TLR
responsiveness in the second bacterial challenge
due to down-regulation of the IRAK1 signaling
protein, which is involved in NF-jB activation
[37]. IRAK1 phosphorylation leads to the
activation of NF-jB and AP-1, which are two
transcription factors that induce the up-
regulation of IL-8 and hBD-2 in airway
epithelial cells [38]. Although this in vitro
model only measured the production of IL-8,
not hBD-2, these results provide a mechanistic
explanation for the reduced levels of hBD-2
expression in the chronic stage of pulmonary
infection in CF patients [39]. Furthermore, the
reduced expression of hBD-2 in the lung in
advanced chronic pulmonary infection (owing
to decreased TLR responsiveness) provides
further insight as to why P. aeruginosa only
colonizes the lung post-S. aureus and
H. influenzae infection. Moreover, this
underscores the potential influence of hBD-2
in the progression of chronic pulmonary
infection in CF patients. The down-regulation
of TLR4 expression in the airway epithelia in
response to acute infection may result in
reduced hBD-2 expression, promoting P.
aeruginosa colonization [40].
Neutrophil and Macrophage Infiltration
Contribute to Degradation of hBD-2
in the CF Lung
Inflammation is a protective tissue response to
infection or injury. In the context of the CF
lung, the inflammatory responses induced by
P. aeruginosa severely damage the pulmonary
epithelium. Exposure of the airway epithelium
to P. aeruginosa induces the expression of the
potent neutrophil chemokine IL-8, initiating
neutrophil infiltration [41].
Neutrophils are granulocytic
polymorphonuclear leukocytes that play a key
role in innate defense [42]. However, in the CF
lung the abnormal accumulation and
persistence of neutrophils produces an
inflammatory response that severely damages
the lung [43, 44]. The quorum-sensing
controlled production of rhamnolipid by
P. aeruginosa induces rapid necrotic killing of
invading neutrophils, which explains why the
neutrophils do not significantly contribute to
the elimination of P. aeruginosa in the CF lung
[45–47]. In the CF lung, infiltrating neutrophils
and most P. aeruginosa strains secrete elastase—a
serine protease that exerts diverse biological
effects that contribute significantly to the
progression of pulmonary CF disease [48, 49].
Elastase is a potent protease that exerts
antimicrobial activity against most Gram-
negative bacteria, but not against P. aeruginosa
[50]. The viability and morphology of P.
aeruginosa remains unaltered even when
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exposed to neutrophil elastase (NE)
concentrations as high as 25 lM, which is
commonly present in the CF lung [51]. After a
short life span, neutrophils succumb to
apoptosis and subsequent phagocytotic
clearance by macrophages [13].
Cathepsins are cysteine proteases secreted by
macrophages that are involved in the remodeling
of the extracellular matrix [52]. Pulmonary
macrophage influx occurs in response to the
elevated levels of apoptotic neutrophils in the
lungs of CF patients resulting in cathepsin
secretion into the bronchoalveolar fluid (BAF)
of the CF lung [51, 53]. Beta-defensins have a
conserved core structure of three disulfide
bridges, which are susceptible to proteolytic
cleavage by cathepsins present in the BAF [54].
Specifically, cathepsins B, L, and S have been
found to cleave the disulfide bonds of hBD-2 and
hBD-3 resulting in their degradation and loss of
antimicrobial activity [30]. In addition to the
high concentrations of cathepsins in the BAF of
Fig. 1 Compromised hBD-2 function in the CF lung promotes chronic pulmonary infection by the opportunistic pathogen
P. aeruginosa
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the CF lung, the low pH of the CF BAF promotes
optimal enzymatic activity for cathepsin
proteolytic activity; most cathepsins have
optimal proteolytic function in acidic pH and
lose their proteolytic properties at physiologic
pH [52]. The BAF of CF patients is acidic because
of impaired bicarbonate transport across the
pulmonary epithelium caused by the CFTR
mutation [55]. Furthermore, the elevated [Cl-]
present in the BAF resulting from the functional
CFTR defect reduces the efficacy of hBD-2 due to
the reduced electrostatic interaction between the
cationic hBD-2 peptide and the anionic resting
membrane potential of invading microorganisms
[24]. The overexpression of cathepsins during
chronic pulmonary infection may cause
increased degradation of hBD-2, promoting
bacterial colonization and infection [30].
CONCLUSION
Many factors contribute to the pathogenesis of
P. aeruginosa in the lungs of CF patients (Fig. 1).
It is becoming increasingly evident that the
regulation of hBD-2 expression and degradation
has profound implications in pulmonary
infections. hBD-2 is an indicator of
inflammation and an essential component
of the innate immune system. The regulation
of hBD-2 activity, expression, and prevention of
degradation (cathepsin inhibitors) are potential
therapeutic options for CF patients that may
decrease the high rates of morbidity and
mortality associated with this common genetic
disease.
ACKNOWLEDGMENTS
This project was funded by an Undergraduate
Student Research Award from the Natural
Sciences and Engineering Research Council of
Canada. Dalcin is the guarantor for this article,
and takes responsibility for the integrity of the
work as a whole.
Conflict of interest. Dalcin and Dr Ulanova
declare no conflict of interest.
Compliance with ethics. The analysis in this
article is based on previously conducted studies,
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Bals R, Weiner DJ, Wilson JM. The innate immune
system in cystic fibrosis lung disease. J Clin Invest.
1999;103:303–7.
2. Dodge JA, Morison S, Lewis PA, et al. Incidence,
population, and survival of cystic fibrosis in the UK,
1968–95. Arch Dis Child. 1997;77:493–6.
3. Rommens JM, Lannuzzi MC, Kerem B, et al.
Identification of the cystic fibrosis gene:
chromosome walking and jumping. Science. 1989;
245:1059–65.
4. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic
fibrosis: a worldwide analysis of CFTR mutations—
correlation with incidence data and application to
screening. Hum Mutat. 2002;19:575–606.
5. Zhou Y, Song K, Painter RG, et al. Cystic fibrosis
transmembrane conductance regulatory
recruitment to phagosomes in neutrophils.
J Innate Immun. 2013;5:219–30.
6. Knowles M, Gatzy J, Boucher R. Increased
bioelectric potential difference across respiratory
164 Infect Dis Ther (2013) 2:159–166
123
epithelia in cystic fibrosis. N Engl J Med.
1981;305:1489–95.
7. Rajan S, Saiman L. Pulmonary infections in patients
with cystic fibrosis. Semin Respir Infect.
2002;17:47–56.
8. Hoiby N, Frederiksen B. Microbiology of cystic
fibrosis. In: Hodson ME, Geddes DM, editors.
Cystic Fibrosis. London: Arnold; 2000, p. 83–107.
9. Emerson J, Rosenfeld M, McNamara S, Ramsey B,
Gibson RL. Pseudomonas aeruginosa and other
predictors of mortality and morbidity in young
children with cystic fibrosis. Pediatr Pulmonol.
2002;34:91–100.
10. Hancock RE. Resistance mechanisms in
Pseudomonas aeruginosa and other nonfermentative
gram-negative bacteria. Clin Infect Dis.
1998;27:93–9.
11. Stover CK, Pham XQ, Erwin AL, et al. Complete
genome sequence of Pseudomonas aeruginosa PAO1, an
opportunistic pathogen. Nature. 2000;406:959–64.
12. Oliver A, Canton R, Campo P, Baquero F, Blazquez
J. High frequency of hypermutable Pseudomonas
aeruginosa in cystic fibrosis lung infection. Science.
2000;288:1251–3.
13. Watt AP, Courtney J, Moore J, Ennis M, Elborn JS.
Neutrophil cell death, activation and bacterial
infection in cystic fibrosis. Thorax. 2005;60:
659–64.
14. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO,
Teran LM. Antimicrobial peptides: general overview
and clinical implications in human health and
disease. Clin Immunol. 2010;135:1–11.
15. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-
component regulatory system of Pseudomonas
aeruginosa that modulates resistance to cationic
antimicrobial peptides and addition of
aminoarabinose to lipid A. J Bacteriol.
2004;186:545–79.
16. Pinheiro da Silva F, Machado MC. Antimicrobial
peptides: clinical relevance and therapeutic
implications. Peptides. 2012;36:308–14.
17. Yang D, Chertov O, Bykovskaia SN, et al. Beta-
defensins: linking innate and adaptive immunity
through dendritic and T cell CCR6. Science.
1999;286:525–8.
18. Boniotto M, Jordan WJ, Eskdale J, et al. Human
beta-defensin 2 induces a vigorous cytokine
response in peripheral blood mononuclear cells.
Antimicrob Agents Chemother. 2006;50:1433–41.
19. Tsustumi-Ishii Y, Nagaoka I. NF-kappa B-mediated
transcriptional regulation of human beta-defensin-
2 gene following lipopolysaccharide stimulation.
J Leukoc Biol. 2002;71:154–62.
20. Bals H, Hiemstra PS. Innate immunity in the lung:
how epithelial cells fight against respiratory
pathogens. Eur Respir J. 2004;23:327–33.
21. Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB,
Wilson JM. Human airway epithelial cells sense
Pseudomonas aeruginosa infection via recognition of
flagellin by Toll-like receptor 5. Infect Immun.
2005;73:7151–60.
22. Joly S, Maze C, McCray PB Jr, Guthmiller JM.
Human beta-defensins 2 and 3 demonstrate strain-
selective activity against oral microorganisms.
J Clin Microbiol. 2004;42:1024–9.
23. Harder J, Meyer-Hoffert U, Teran LM, et al. Mucoid
Pseudomonas aeruginosa, TNF-alpha, and IL-1 beta,
but not IL-6, induce human beta-defensin-2 in
respiratory epithelia. Am J Respir Cell Mol Biol.
2000;22:714–21.
24. Bals R, Wang X, Wu Z, et al. Human beta-defensin 2
is a salt-sensitive peptide antibiotic expressed in
human lung. J Clin Invest. 1998;102:874–80.
25. Schro¨der JM, Harder J. Human beta-defensin-2. Int
JBiochem Cell Biol. 1999;31:645–51.
26. Schibli DJ, Hunter HN, Aseyev V, et al. The solution
structures of the human beta-defensins lead to a
better understanding of the potent bactericidal
activity of HBD3 against Staphylococcus aureus.
J Biol Chem. 2002;277:8279–89.
27. Zasloff M. Antimicrobial peptides of multicellular
organisms. Nature. 2002;415:389–95.
28. Powers JP, Hancock RE. The relationship between
peptide structure and antibacterial activity.
Peptides. 2003;24:1681–91.
29. Corrales-Garcia LL, Possani LD, Corzo G. Expression
systems of human b defensins: vectors, purification
and biological activities. Amino Acids. 2011;40:5–13.
30. Taggart CC, Greene CM, Smith SG, et al.
Inactivation of human beta-defensins 2 and 3 by
elastolytic cathepsins. J Immunol. 2003;171:931–7.
31. Smith EE, Buckley DG, Wu Z, et al. Genetic
adaptation by Pseudomonas aeruginosa to the
airways of cystic fibrosis patients. Proc Natl Acad
Sci USA. 2006;103:8487–92.
32. Jelsbak L, Johansen HK, Frost AL, et al. Molecular
epidemiology and dynamics of Pseudomonas
Infect Dis Ther (2013) 2:159–166 165
123
aeruginosa populations in the lungs of cystic fibrosis
patients. Infect Immun. 2007;75:2214–24.
33. Cobb LM, Mychaleckyj JC, Wozniak DJ, Lopez-Boado
YS. Pseudomonas aeruginosa flagellin and alginate elicit
very different gene expression patterns in airway
epithelial cells: implications for cystic fibrosis
disease. J Immunol. 2004;173:5659–70.
34. Soutourina OA, Bertin PN. Regulation cascade of
flagellar expression in Gram-negative bacteria.
FEMS Microbiol Rev. 2006;274:505–23.
35. Hayashi F, Smith KD, Ozinsky A, et al. The innate
immune response to bacterial flagellin is mediated
by Toll-like receptor 5. Nature. 2001;410:1099–103.
36. Chow JC, Young DW, Golenbock DT, Christ WJ,
Gusovsky F. Toll-like receptor-4 mediates
lipopolysaccharide-induced signal transduction.
J Biol Chem. 1999;288:10689–92.
37. Wu Q, Lu Z, Verghese MW, Randell SH. Airway
epithelial cell tolerance to Pseudomonas aeruginosa.
Respir Res. 2005;6:26.
38. Wehkamp J, Harder J, Wehkamp K, et al. NF-kappaB-
and AP-1-mediated induction of human beta
defensin-2 in intestinal epithelial cells by Escherichia
coli Nissle 1917: a novel effect of a probiotic
bacterium. Infect Immun. 2004;72:5750–8.
39. Chen CI, Schaller-Bals S, Paul KP, Wahn U, Bals R.
Beta-defensins and LL-37 in bronchoalveolar lavage
fluid of patients with cystic fibrosis. J Cyst Fibros.
2004;3:45–50.
40. MacRedmond R, Greene C, Taggart CC, McElvaney
N, O’Neill S. Respiratory epithelial cells require Toll-
like receptor 4 for induction of human beta-
defensin 2 by lipopolysaccharide. Respir Res.
2005;6:1–11.
41. Greene CM, Carroll TP, Smith SG, et al. TLR-
induced inflammation in cystic fibrosis and non-
cystic fibrosis airway epithelial cells. J Immunol.
2005;174:1638–46.
42. Baggiolini M, Dewald B. The neutrophil. Int Arch
Allergy Immunol. 1985;76:13–20.
43. Doring G. The role of neutrophil elastase in chronic
inflammation. Am JRespir Crit Care Med.
1994;150:S114–7.
44. Dunlevy FK, Martin SL, de Courcey F, Elborn JS,
Ennis M. Anti-inflammatory effects of DX-890, a
human neutrophil elastase inhibitor. J Cyst Fibros.
2012;11:300–4.
45. Jensen PO, Bjarnsholt T, Phipps R, et al. Rapid
necrotic killing of polymorphonuclear leukocytes is
caused by quorum-sensing-controlled production
of rhamnolipid by Pseudomonas aeruginosa.
Microbiology. 2007;153:1329–38.
46. Alhede M, Bjarnsholt T, Jensen PO, et al.
Pseudomonas aeruginosa recognizes and responds
aggressively to the presence of polymorphonuclear
leukocytes. Microbiology. 2009;155:3500–8.
47. Van Gennip M, Christensen LD, Alhede M, et al.
Inactivation of the rhlA gene in Pseudomonas
aeruginosa prevents rhamnolipid production,
disabling the protection against polymorphonuclear
leukocytes. APMIS. 2009;117:537–46.
48. Wretlin B, Pavlovskis OR. Pseudomonas aeruginosa
elastase and its role in pseudomonas infections.
RevInfect Dis. 1983;5(Suppl 5):S998–1004.
49. Tirouvanziam R. Neutrophilic inflammation as a
major determinant in the progression of cystic
fibrosis. Drug News Perspect. 2006;19:609–14.
50. Sonawane A, Jyot J, During R, Ramphal R.
Neutrophil elastase, an innate immunity effector
molecule, represses flagellin transcription in
Pseudomonas aeruginosa. 2006. Infect Immun.
2006;74:6682–9.
51. Berger M. Inflammation in the lung in cystic
fibrosis. A vicious cycle that does more harm than
good? Clin Rev Allergy. 1991;9:119–42.
52. Wolters PJ, Chapman HA. Importance of lysosomal
cysteine proteases in lung disease. Respir Res.
2000;1:170–7.
53. Ulrich M, Worlitzsch D, Viglio S, et al. Alveolar
inflammation in cystic fibrosis. J Cyst Fibros.
2010;9:217–27.
54. Hoover DM, Rajashankar KR, Blumenthal R, et al.
The structure of human beta-defensin-2 shows
evidence of higher order oligomerization. J Biol
Chem. 2000;275:32911–8.
55. Tate S, MacGregor G, Davis M, Innes JA, Greening
AP. Airways in cystic fibrosis are acidified: detection
by exhaled breath condensate. Thorax. 2002;57:
926–9.
166 Infect Dis Ther (2013) 2:159–166
123
